Just when renal replacement therapy should start after acute kidney injury has been debated.
Acute kidney injury happens often in critically ill patients, and has been a common feature of coronavirus disease 2019 (COVID-19). Many of these patients require renal replacement therapy, such as dialysis.
However, just when renal replacement therapy should start has been debated. Results from a team across several institutions who sought to answer this question, including the STARRT-AKI investigators, and scientists from Canada, Australia, New Zealand, and Ireland, appeared recently in the New England Journal of Medicine.
Investigators randomized 3019 patients, and 2927 were included in the intent-to-treat analysis; 1465 were treated in an accelerated strategy that started renal replacement therapy within 12 hours after the patient met criteria, while 1462 received the standard strategy, in which therapy was not started for at least 3 days (at least 72 hours). The primary outcome was death from any cause at 90 days.
In the accelerated group, 1418 (96.8%) received therapy, while 903 (61.8%) received treatment in the standard group. At 90 days, death occurred in 643 patients in the accelerated group (43.9%), and in 639 (43.7%) in the standard group, for a relative risk of 1.00 (95% CI, 0.93-1.09, P = .92).
Of those who lived at least 90 days, ongoing dependence on renal replacement therapy was seen in 85 of the 814 patients (10.4%) in the accelerated strategy group, and in 49 of the 815 patients (6.0%) of the standard group, for a relative risk of 1.74 (95% CI, 1.24-2.43).
In the accelerated group, 346 of the 1503 (23.0%) had adverse events, while 245 of 1489 (16.5%) in the standard group (P < .001) did so.
“Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy,” the authors concluded.
Reference
The STARRT-AKI Investigators, et al. Timing of initiation of renal-replacement therapy in acute kidney injury [published online July 16, 2020]. N Engl J Med. DOI: 10.1056/NEJMoa2000741
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
Identifying Chronic Kidney Disease Stage 3 With Excess Disease Burden
June 24th 2024A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention.
Read More